Finding new drugs for cancer treatment and non-hormonal contraception
Official title: DEL Screening Campaign for Contraceptive and Cancer Targets
Funded at University of Minnesota · NIH-10870842 · Data updated 2026-11-12
This study is looking for new drugs that can help treat cancer and provide non-hormonal birth control by targeting specific proteins in the body, aiming to find options that work well without the usual side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $232,500 |
| NIH project number | 1R21HD115181-01 |
| Project ID | NIH-10870842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals seeking effective cancer therapies or those interested in non-hormonal contraception options.
✕Less likely to help
Patients who are already using hormonal contraceptives or those who do not have cancer may not benefit from this research.
What this research studies
This research aims to discover new allosteric inhibitors that can selectively target specific protein kinases involved in cancer and contraception. By screening a library of compounds, the researchers will identify potential drugs that could provide effective cancer chemotherapy without the typical side effects, as well as reversible non-hormonal contraceptive options. The study focuses on four key kinases, including those that could be used for both male and female contraception. The process involves synthesizing and testing these compounds through various biochemical assays to confirm their effectiveness and safety.
Why it matters
Potential benefit: If successful, this research could lead to safer cancer treatments and new non-hormonal contraceptive methods.
How similar studies have gone: Previous research has shown promise in the field of allosteric inhibition, but this specific approach targeting these kinases is relatively novel.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Georg, Gunda I. — University of Minnesota
- Study coordinator: Georg, Gunda I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.